Τίτλος:
Is locally advanced head-neck cancer one more candidate for accelerated hypofractionation?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: Hypofractionated accelerated radiotherapy (HypoAR) is widely applied for the treatment of early laryngeal cancer. Its role in locally advanced head-neck cancer (LA-HNC) is unexplored. Patients and Methods: We present results of a prospective trial on 124 patients with LAHNC, treated with radio-chemotherapy with three different HypoAR fractionations (3.5 Gy/day × 14-15 fractions, 2.7 Gy/day × 20-21 fractions, and 2.5 Gy/day × 21-22 fractions). Results: Protraction of the overall treatment time due to oropharyngeal mucositis was enforced in 18/57 laryngeal, 6/19 nasopharyngeal, and 15/48 cancer patients with other tumors. Regarding late toxicities, laryngeal edema grade 3 was noted in 5/57 patients with laryngeal cancer, while severe dysphagia was noted in 4/124 and tracheoesophageal fistula formation in 1/124 patients. The complete response rates obtained were 73%, 84%, and 67% in patients with laryngeal, nasopharyngeal, and other tumors, respectively. The 3-year locoregional progression-free survival was 58%, 73%, and 55%, respectively. Conclusion: HypoAR chemoradiotherapy is feasible, with acceptable early and late radiotherapy toxicities, response rates and LPFS. © 2021 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
KOUKOURAKIS, I.M.
ZYGOGIANNI, A.
KOULOULIAS, V.
KYRGIAS, G.
PANTELIADOU, M.
NANOS, C.
ABATZOGLOU, I.
KOUKOURAKIS, M.I.
Περιοδικό:
ANTICANCER RESEARCH
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
amifostine; cetuximab; chlorhexidine; cisplatin; codeine phosphate; docetaxel; fluorouracil; mouthwash; paracetamol; posaconazole, acute toxicity; adenocarcinoma; adult; advanced cancer; aged; analgesia; anaplastic carcinoma; Article; cancer combination chemotherapy; cancer patient; cancer radiotherapy; cancer survival; chemoradiotherapy; clinical target volume; computer assisted tomography; conformal radiotherapy; controlled clinical trial; controlled study; dysphagia; female; follow up; gross tumor volume; head and neck cancer; head and neck squamous cell carcinoma; human; hypofractionated accelerated radiotherapy; hypofractionated radiotherapy; hypopharynx cancer; image guided radiotherapy; induction chemotherapy; intensity modulated radiation therapy; larynx cancer; larynx carcinoma; larynx edema; local disease free survival; local progression free survival; major clinical study; male; mouth cancer; mouth hygiene; mucosa inflammation; multiple cycle treatment; mycosis; nasopharynx cancer; neck cancer; organs at risk; oropharynx; oropharynx cancer; pharyngitis; physical examination; planning target volume; primary tumor; priority journal; progression free survival; prospective study; radiation dose fractionation; radiation injury; radiation response; radiotherapy dosage; sarcoma; swallowing; therapy delay; tooth brushing; tracheoesophageal fistula; treatment duration; volumetric modulated arc therapy; adverse event; cancer staging; head and neck tumor; intensity modulated radiation therapy; Kaplan Meier method; metastasis; middle aged; mortality; multimodality cancer therapy; pathology; procedures; prognosis; treatment outcome; very elderly; young adult, Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Radiation Dose Hypofractionation; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Treatment Outcome; Young Adult
DOI:
10.21873/anticanres.14797
